SCHEMBL419611

SCHEMBL419611

CCOC(=O)c1cc(-c2cccc(Cl)c2)c(-c2ccc(F)cc2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.47
MAOB P27338 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
SHMT1 P34896 1/20 0.40
PTGES O14684 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GABRA2 P47869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421473 0.91 ALOX5 (0.56) ALOX5MAOBTRPM8L3MBTL1KDM4E
SCHEMBL420126 0.83 ALOX5 (0.45) ALOX5MAOBTRPM8L3MBTL1KDM4E
SCHEMBL2487648 0.83 ALOX5 (0.41) ALOX5TRPM8L3MBTL1MAPTSHMT1
SCHEMBL459848 0.82 NR4A1 (0.42) RAB9ASHMT1POLBGABRA2GABRB2
SCHEMBL417516 0.80 ALOX5 (0.49) ALOX5MAOBTRPM8L3MBTL1KDM4E
SCHEMBL417954 0.78 ALOX5 (0.40) ALOX5MAOBL3MBTL1NPC1MAPT
SCHEMBL419840 0.78 FNTA (0.42) ALOX5MAOBKDM4EALDH1A1CYP1A2
SCHEMBL421079 0.78 ALOX5 (0.55) ALOX5MAOBTRPM8L3MBTL1MAPT
SCHEMBL16438615 0.76 JAK2 (0.48) ALOX5TRPM8L3MBTL1MAPTSMN1; SMN2
SCHEMBL417915 0.76 MAPT (0.45) TRPM8L3MBTL1KDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-8324268-B2 Substituted furancarboxamides, and use thereof AICURIS GMBH & CO. KG (DE) 2012-12-04 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AICURIS GMBH & CO. KG (DE) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022059-A1 SUBSTITUTED FURANCARBOXAMIDES, AND USE THEREOF AADAC, DDC, TPMT ALOX5 948/4885MAOB 272/4885TRPM8 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.